Antibiotice achieved its forecasted profit target for the first half of 2015

The revenues from sales of the Antibiotice Company during the first half of the year 2015 amounted to 132.39 million lei, up by 1% compared to the amount planned in the Revenues and Expenditure Budget. The gross profit recorded during the first 6 months of the year amounted to 16.6 million lei, an amount budgeted at the beginning of the year and the net profit recorded the level of 15.3 million lei.

If the value of the claw back tax recorded during the first six months of 2015 were at the level of last year, the gross profit of the period would have reached 23.1 million lei, by 1.2 million lei higher than the first semester of 2014.

For the first six months of the year 2015, the Antibiotice Company has established through its Revenues and Expenditure Budget a sales value 11.5% lower than the figure achieved in the year 2014 amid the slow down of the purchases performed by pharmacies in anticipation of new prices for the POM, but also because of the claw back tax increase. Thus, the company’s efforts aimed at reducing existing stocks in pharmacies and the sales from distribution to pharmacies and hospitals given that the pharmaceutical market has stagnated or even declined in consumption.

According to the data provided by Cegedim, for the outputs of pharmacies and hospitals the Antibiotice Company recorded a 19% increase compared to the same period last year, from 119.1million lei to 141.8 million lei, while the market grew only by 3.3%.

The fact that the Antibiotice Company managed to reduce the stocks in pharmacies and reached the profit and sales target established in the REB provides favorable conditions to achieve the annual indicators estimated in the Revenues and Expenditure Budget.

Sales on the foreign markets during the first half of 2015 amounted 45.9 million lei, a value similar to the one recorded during the first half of the year 2014.
In the near future an increase in the exports of Nystatin is expected, as a result of the fact that two of our partners on the US market obtained the FDA approval, as well as due to new partnerships concluded for finished products. The Antibiotice Company seeks to expand its exports on the Asian market. Thus, its activity in South-East Asia will unfold due to the opening of a representative office in Vietnam, but also in Sub-Saharan Africa through a partnership with a company in Ethiopia for the commercialization of 22 products in this country and in that region.

After the first six months of the year 2015, our company ranks in the top four of the prescription and generic companies, with a market share of 8.48%. Also, on the domestic pharmaceutical market, the Antibiotice Company ranks 13th with a market share of 2.33%, compared to the same period last year when our company had a market share of 2.02%.